リボシクリブ療法を受けた患者の転移性乳がんにおける疾患進行としてマスクしたデズモイド型線維症: 症例報告
Ha Rim Ahn1,2, Ae Ri Ahn2,3, Hyun Jo Youn1,4
1Department of Surgery, Jeonbuk National University Medical School, Jeonju, Korea.
Journal of breast cancer
|September 1, 2025
まとめ
リボシクリブとアロマターゼ阻害剤を併用した患者の乳房に発生した希少な腫瘍は,当初,がんの進行と疑われていた. 手術後の病理学では デスモイド型の線維腫が 明らかになり,正確な診断の必要性が 強調されました.
科学分野:
- 腫瘍学
- 病理学について
背景:
- HR+ HER2転移性乳がんの第一線療法には,しばしばリボシクリブとアロマターゼ阻害剤 (AIs) が含まれる.
- デスモイド型線維症 (DTF) は,画像で悪性腫瘍を模倣できる希少で局所的に侵襲的な軟組織腫瘍である.
さらに関連する動画
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.3K
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
1.2K
関連する概念動画
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
